ScreenerHero

KYMR Kymera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · kymeratx.com
109.85USD+2.29%Mkt Cap: 9.13B $P/E: —

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap9.13B USD
Enterprise Value8.32B USD
Revenue (TTM)105.00M USD
Gross Profit-270.57M USD
Net Income (TTM)-311.35M USD
Revenue/Share1.13 USD
Last Price109.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees273
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.06
PEG—
EV/EBITDA-24.47
EV/Revenue79.21
P/S85.04
P/B5.89
EPS (TTM)-3.25
EPS (Forward)-5.10
52W Range
50.3575% of range130.05
52W High130.05 USD
52W Low50.35 USD
Profitability
Gross Margin-257.69%
Oper. Margin-116.32%
EBITDA Margin0.00%
Profit Margin-794.04%
ROE-19.71%
ROA-17.86%
Growth
Revenue Growth466.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-232.89M USD
CapEx (TTM)1.45M USD
FCF Margin-137.21%
FCF Yield-1.58%
Net Debt-612.43M USD
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity0.05
Current Ratio10.34
Quick Ratio9.97
Book Value/Sh18.23 USD
Cash/Share8.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)138.64 USD
Upside (mean)+26.2%
Target Range111.00 USD – 180.00 USD
111.00+26.2% to mean180.00
# Analysts22
Ownership
Shares Out.83.15M
Float66.04M
Insiders2.12%
Institutions119.28%
Short Interest
Short Ratio16.4d
Short % Float16.29%
Short % Out.12.66%
Shares Short10.53M
Short (prev mo.)10.38M
Technical
SMA 50114.47 (-4.0%)
SMA 20093.03 (+18.1%)
Beta1.97
S&P 52W Chg14.58%
Avg Vol (30d)711.69K
Avg Vol (10d)804.18K
Technical Indicators
RSI (14)43.7
MACD-1.2675
MACD Signal-0.1877
MACD Hist.-1.0798
BB Upper121.50 USD
BB Middle114.43 USD
BB Lower107.37 USD
BB Width12.34%
ATR (14)5.366 USD
Vol Ratio (20d)0.93x